Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
M E Falagas, K Z Vardakas

Abstract

Linezolid is an oxazolidinone, a new class of antibacterial with a unique mechanism of action, namely inhibition of the formation of a functional 70S initiation complex in the 50S bacterial ribosomal subunit. Linezolid is highly active against multidrug-resistant Gram-positive cocci, including meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate and vancomycin-resistant S. aureus, and vancomycin-resistant enterococci; its spectrum of activity also includes some anaerobic bacteria. Linezolid has been studied in several randomized controlled trials for the treatment of patients with community-acquired and nosocomial pneumonia, skin and soft tissue infections (SSTIs), urinary tract infections and bacteraemia. The available evidence suggests that linezolid is at least as effective as vancomycin for patients with nosocomial pneumonia, and there are some retrospective analyses supporting its superiority in comparison with vancomycin for MRSA nosocomial pneumonia, including ventilator-associated pneumonia. Linezolid is more effective than glycopeptides, macrolides and beta-lactams for SSTIs. The limited available data for the treatment of patients with bacteraemia suggest that it may be a better treatment option ...Continue Reading

References

Apr 1, 1996·Antimicrobial Agents and Chemotherapy·G E ZurenkoS J Brickner
Oct 23, 1997·Antimicrobial Agents and Chemotherapy·D L ShinabargerJ M Buysse
Sep 1, 2000·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·M J RichardsR P Gaynes
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group
May 23, 2001·The Pediatric Infectious Disease Journal·S L KaplanUNKNOWN Linezolid Pediatric Pheumonia Study Group. Pharmacia and Upjohn
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·John E ConteElisabeth Zurlinden
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dennis L StevensBarry Hafkin
Jul 4, 2002·The Journal of Antimicrobial Chemotherapy·A M LoveringA P MacGowan
Sep 13, 2002·The Medical Journal of Australia·Carmela E Corallo, Amalie E Paull
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·D AndesW A Craig
Oct 31, 2002·The Journal of Antimicrobial Chemotherapy·B RanaC M Tobin
Dec 13, 2002·Scandinavian Journal of Infectious Diseases·Gerry S San PedroUNKNOWN Linezolid Community-Acquired Pneumonia Study Group
Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mary C BirminghamJerome J Schentag
May 23, 2003·Antimicrobial Agents and Chemotherapy·Ethan RubinsteinJack Remington
May 27, 2003·Paediatric Drugs·Katherine A Lyseng-Williamson, Karen L Goa
Jul 11, 2003·Clinical Therapeutics·Richard G WunderinkUNKNOWN Linezolid Nosocomial Pneumonia Study Group
Aug 13, 2003·The Pediatric Infectious Disease Journal·Sheldon L KaplanUNKNOWN Linezolid Pediatric Study Group
Oct 2, 2003·The Pediatric Infectious Disease Journal·Lisa SaimanJon B Bruss
Oct 9, 2003·Clinical Pharmacokinetics·Dennis J Stalker, Gail L Jungbluth
Oct 30, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elsie LeeRobert Press
Dec 18, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A LipskyUNKNOWN Linezolid Diabetic Foot Infections Study Group
Jan 20, 2004·The Journal of Antimicrobial Chemotherapy·Mark WilcoxMatthew Dryden
Feb 10, 2004·Intensive Care Medicine·Malina Ioanas, Hartmut Lode
Aug 4, 2004·The Lancet Infectious Diseases·Adam M BresslerJyoti Somani
Oct 16, 2004·Expert Review of Anti-infective Therapy·Dennis L StevensKarl Madaras-Kelly
Dec 28, 2004·American Journal of Surgery·John WeigeltRobert N Swanson
Mar 15, 2005·Scandinavian Journal of Infectious Diseases·Petros KopteridesApostolos Armaganidis
May 18, 2005·The Journal of Infectious Diseases·Jared A SilvermanJeff Alder
May 27, 2005·Antimicrobial Agents and Chemotherapy·John WeigeltUNKNOWN Linezolid CSSTI Study Group
Oct 1, 2005·The Journal of Antimicrobial Chemotherapy·Andrew F ShorrMarin Kollef
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luis E JaureguiWilliam O'Riordan
Feb 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Branimir JaksicKenneth J Tack
Apr 20, 2006·Injury·P J HarwoodP V Giannoudis
Jun 1, 2006·The Journal of Antimicrobial Chemotherapy·Matthew E FalagasKonstantinos Z Vardakas

❮ Previous
Next ❯

Citations

Nov 4, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A SimonA Müller
Jan 22, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·K Z VardakasM E Falagas
May 6, 2011·The Journal of Antimicrobial Chemotherapy·F Kate Gould
Oct 28, 2009·The Pediatric Infectious Disease Journal·Michel Erlewyn-LajeunesseSaul N Faust
Apr 18, 2009·Current Opinion in Pulmonary Medicine·Evelina Tacconelli, Giulia De Angelis
Jul 13, 2012·Infection and Drug Resistance·Sally Ager, Kate Gould
Dec 18, 2010·Future Microbiology·Rasmus V RasmussenNiels E Bruun
Apr 3, 2014·The Journal of Antibiotics·Tianlin WangLihua Mu
Apr 2, 2010·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Liesbet De BusHans Van Vlierberghe
May 12, 2010·Expert Review of Anti-infective Therapy·Adam R Renslo
Jun 23, 2009·Expert Opinion on Drug Safety·Eugenios I Metaxas, Matthew E Falagas
May 24, 2011·Médecine et maladies infectieuses·M MontserratL Beretz
Jul 5, 2012·Chemotherapy·Thomas GrügerJosef Zündorf
Mar 23, 2011·Drug Metabolism and Drug Interactions·Amy C GoMichelle A Barron
Nov 13, 2018·The Journal of Antimicrobial Chemotherapy·Sarah C J JorgensenMichael J Rybak
Jun 1, 2018·Nature Reviews. Disease Primers·Andie S LeeStephan Harbarth
Oct 26, 2013·The Journal of Trauma and Acute Care Surgery·Stephen W DaviesRobert G Sawyer
Sep 1, 2014·Irish Journal of Psychological Medicine·C ClarkeJ Cooney
Dec 7, 2020·Journal of Global Antimicrobial Resistance·Yuhang WangYun Cai
Aug 19, 2021·Infection & chemotherapy·Wichai SantimaleeworagunSudaluck Thunyaharn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.